Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group - sprookjes - yvandenbroek - TriplyDB

Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group

Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group

http://www.wikidata.org/entity/Q35552069

about

Cholesterol biosynthesis pathway as a novel mechanism of resistance to estrogen deprivation in estrogen receptor-positive breast cancer Genomic profiling in luminal breast cancer Cancer across the tree of life: cooperation and cheating in multicellularity Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration.Prognostic value of Ki-67 for prostate cancer death in a conservatively managed cohort.Prognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients.Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Epidermal growth factor receptor immunohistochemistry: new opportunities in metastatic colorectal cancer From bench to bedside: What do we know about hormone receptor-positive and human epidermal growth factor receptor 2-positive breast cancer?Digital quantification of gene expression in sequential breast cancer biopsies reveals activation of an immune response How reliable is Ki-67 immunohistochemistry in grade 2 breast carcinomas? A QA study of the Swiss Working Group of Breast- and Gynecopathologists Respective prognostic value of genomic grade and histological proliferation markers in early stage (pN0) breast carcinoma Loss of DLG5 promotes breast cancer malignancy by inhibiting the Hippo signaling pathway.Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial.Involvement of macrophage migration inhibitory factor and its receptor (CD74) in human breast cancer.Discordance Rate in Estrogen Receptor, Progesterone Receptor, HER2 Status, and Ki67 Index Between Primary Unifocal and Multiple Homogenous Breast Carcinomas and Synchronous Axillary Lymph Node Metastases Have an Impact on Therapeutic Decision.Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 Neoadjuvant epirubicin, gemcitabine and docetaxel for primary breast cancer: long-term survival data and major prognostic factors based on two consecutive neoadjuvant phase I/II trials.Scientific and Regulatory Policy Committee (SRPC) Review: Interpretation and Use of Cell Proliferation Data in Cancer Risk Assessment.A methodology for comprehensive breast cancer Ki67 labeling index with intra-tumor heterogeneity appraisal based on hexagonal tiling of digital image analysis data.Assessing the clinical utility of genomic expression data across human cancers.Mechanistic elucidation of the antitumor properties of withaferin a in breast cancer.Ki-67 protein expression and tumor associated inflammatory cells (macrophages and mast cells) in canine colorectal carcinoma.Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer.Tumor growth rate of invasive breast cancers during wait times for surgery assessed by ultrasonography Ki-67 is a PP1-interacting protein that organises the mitotic chromosome periphery.Ki-67 is a strong prognostic marker of non-small cell lung cancer when tissue heterogeneity is considered An international reproducibility study validating quantitative determination of ERBB2, ESR1, PGR, and MKI67 mRNA in breast cancer using MammaTyper®The role of the pathologist in the decision-making process.Optimal approach in early breast cancer: Adjuvant and neoadjuvant treatment.Chromatin CKAP2, a new proliferation marker, as independent prognostic indicator in breast cancer Immunohistochemical quantification of the vitamin B12 transport protein (TCII), cell surface receptor (TCII-R) and Ki-67 in human tumor xenografts.Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index A methodology to ensure and improve accuracy of Ki67 labelling index estimation by automated digital image analysis in breast cancer tissue Sex-related differences of urethane and sodium valproate effects on Ki-67 expression in urethane-induced lung tumors of mice Evaluation of FLT-PET-CT as an imaging biomarker of proliferation in primary breast cancer.Inflammation of mammary adipose tissue occurs in overweight and obese patients exhibiting early-stage breast cancer A novel model for Ki67 assessment in breast cancer.Evaluating the response of neoadjuvant chemotherapy for treatment of breast cancer: are tumor biomarkers and dynamic contrast enhanced MR images useful predictive tools?Survivin family proteins as novel molecular determinants of doxorubicin resistance in organotypic human breast tumors.

P2860

Q24658633-8D33B45C-CD92-4215-920F-51A2938917A4 Q26862681-E66B6AC4-B64D-4C01-ABD3-88C622711245 Q27026902-3C1E53EF-1703-420C-918C-FB8FF3C656BB Q27304609-D50C22A7-B85E-4E8F-B441-5145284BEE46 Q27852034-00CAE29B-6846-466F-8708-406EE3CA5EA7 Q27853207-B37FC8C1-307A-41AF-86B7-0073A990E695 Q28079118-74880275-3892-470A-BA29-7C4FB6F318FD Q28084216-0F2ABB24-2576-41DF-AE19-63F7BAFDA511 Q28084982-6FE54966-20B1-4D98-A312-45753D196AF4 Q28533543-96ECA3C1-06BE-4E80-AF8F-8FEA114E4208 Q28729183-238A975C-8BD3-4E69-9E7E-97A93D60E357 Q28730529-9648A905-6EF9-4B2F-A087-DF4CE4304832 Q29871425-082FE595-A546-4678-A77B-FF6FF495040C Q30315367-404A7681-93CF-4385-A269-1942C8C22759 Q30435034-CA38000E-B0E9-4010-85EF-0F439F2DD123 Q30490708-16375DDD-C5CD-436F-9A45-244EF44A0C59 Q30543788-36D5AA80-B01F-4D73-881E-283D74D8DF39 Q30588206-5C4B9FBD-EA94-4167-BFA1-F3A79D04CD67 Q30938639-45DF4A9B-F848-4F0A-9395-8F7A7B189973 Q31007935-8FE1CA13-9E6C-4212-977E-567082AA2476 Q31109151-E361FAEF-67D4-45B2-BE69-3D14C3EC8DE5 Q33563815-8F793103-4867-4D5B-B3AC-1C57B100176F Q33582044-D5BF33A9-08C9-46BE-8985-906A79371BD6 Q33591751-09F5540F-819A-4574-9AF0-9CBF0C0F3373 Q33595402-DC6FF901-0EF8-4DD6-8D3B-DFCB74325CE4 Q33654272-0CFB2FEA-319D-4EF4-A376-F486DD013D69 Q33655228-A4225825-A2AC-4EC4-8807-CE130A2C15E0 Q33660598-2E75BFF5-1742-4414-8B7F-B29EBDA72F30 Q33697907-B71DC291-4579-4D84-9E3D-39636ACA5B6A Q33698446-93BE41F3-D0B0-4121-A086-F3884495456C Q33699104-2A71AB1C-4B29-48BB-9120-799329994410 Q33702468-9B1DBEC2-957A-4AF1-ABF0-D2BF356E3F7A Q33717341-C864D933-5D17-4015-BC9C-3C8B4FDCC7D8 Q33739487-3FCD6358-75F7-4B45-8D3F-7D6950E6B6F2 Q33744688-5785F1A1-B7F8-430E-B21A-F55F6BE6EF19 Q33750115-B14B48EB-64C8-4E2F-94A9-D25B6203845F Q33767114-44B2ED0F-C2FA-4440-8A72-FB5BB35CEB83 Q33801255-79961209-CAC4-4F00-89BF-ACCAC7FD94AE Q33814616-3167077B-5D13-4174-8C26-3B4BB25175B2 Q33827053-FA962F8A-7445-4CE5-B8AA-74E023CDBD88

P2860

Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group

http://www.wikidata.org/entity/Q35552069

description

2011 nî lūn-bûn

@nan

2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Assessment of Ki67 in breast c ...... in Breast Cancer working group

@ast

Assessment of Ki67 in breast c ...... in Breast Cancer working group

@en

type

label

Assessment of Ki67 in breast c ...... in Breast Cancer working group

@ast

Assessment of Ki67 in breast c ...... in Breast Cancer working group

@en

prefLabel

Assessment of Ki67 in breast c ...... in Breast Cancer working group

@ast

Assessment of Ki67 in breast c ...... in Breast Cancer working group

@en

P1433

Q35552069-995005F7-6145-465B-8597-EB1A9B4E6E3A

P1476

Q35552069-DC0C96B3-29EA-45C5-91B7-4BF606EED0C3

P2093

Q35552069-0172529A-A624-4B1B-A9CA-B53F76491891

Q35552069-05473ECB-09D1-4553-B081-4D8AB43AF8A3

Q35552069-3050165C-29E8-4B8C-B1CB-CE17727C242B

Q35552069-499D6C04-A721-4B04-81DF-5DB0577E76D3

Q35552069-4B1D34F6-72AC-46E0-9DB8-B3D6C49B65C1

Q35552069-569B021A-E038-4428-9D66-3BA406EC3528

Q35552069-7DC7EFF5-AD34-4EB4-B073-F49590AED299

Q35552069-80A0C7E9-A32A-49AC-B0B1-111D6434309B

Q35552069-8AAF9FA7-2BF4-4B9D-A0A6-72564B142990

Q35552069-922E350B-871F-414F-B118-647DF751E37D

P2860

Q35552069-04E41CA4-E02C-4A76-8687-5E003AB95C74

Q35552069-05D519F9-25AD-4097-AF30-C289B0A342E0

Q35552069-0E407C3F-57FD-4F56-978E-E374B7656B0B

Q35552069-1E4B742B-DF5C-4716-941B-B131A1C528E0

Q35552069-26BAAA68-3BE7-46CC-AC89-A6093515A373

Q35552069-2DF71E6E-698C-47CE-9126-CECBB6EE500F

Q35552069-34E08F08-4953-4156-B703-288107CCA917

Q35552069-353FACEB-6B99-4C89-8A4E-8D329C6113E6

Q35552069-3AECDD9A-C962-46D1-BE4C-62FCEA0BA44A

Q35552069-3D2D8467-D911-48A6-B726-26AEDD287CFC

P304

Q35552069-60ECD81D-A547-4413-8AC0-BBDD72182740

P31

Q35552069-395A1375-D075-4CFF-A015-35817D34BAAE

P356

Q35552069-F0F420E8-F606-4F44-974C-663DA93CB409

P407

Q35552069-382B9231-9934-464B-8A1E-242CA50557CF

P433

Q35552069-DC4ECDB6-EE83-4859-B06C-D7C4444666D7

P478

Q35552069-B7ACDF2F-BC92-4A1B-840A-5ED1003E1BAD

P50

Q35552069-318856C2-DC31-47DA-A356-8786A56E0AE1

Q35552069-594D9B24-586D-4449-8D82-8BB5FA2A6450

Q35552069-869BB5EB-FB17-48E5-B386-4A318289222B

P577

Q35552069-9B45EFEF-A5AF-42F3-82ED-CE798FE70B53

P5875

Q35552069-5ACA0BEF-2CCC-4E5C-AEC9-425F6713FCD3

P698

Q35552069-8FAB9A0C-0DC5-46DA-A85B-44F2A4C27238

P932

Q35552069-AB487327-5AE0-484E-943E-C709B43B6D77

P356

P1433

Journal of the National Cancer Institute

P1476

Assessment of Ki67 in breast c ...... in Breast Cancer working group

@en

P2093

Christos Sotiriou

http://www.w3.org/2001/XMLSchema#string

Daniel F Hayes

http://www.w3.org/2001/XMLSchema#string

Frederique Penault-Llorca

http://www.w3.org/2001/XMLSchema#string

Ian E Smith

http://www.w3.org/2001/XMLSchema#string

International Ki-67 in Breast Cancer Working Group

http://www.w3.org/2001/XMLSchema#string

Jack Cuzick

http://www.w3.org/2001/XMLSchema#string

Janine Salter

http://www.w3.org/2001/XMLSchema#string

Jo Anne Zujewski

http://www.w3.org/2001/XMLSchema#string

John Bartlett

http://www.w3.org/2001/XMLSchema#string

Judith C Hugh

http://www.w3.org/2001/XMLSchema#string

P2860

Outcome and human epidermal growth factor receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling

The Ki-67 protein: from the known and the unknown

American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.

Cetuximab-based immunotherapy and radioimmunotherapy of head and neck squamous cell carcinoma.

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.

Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer

Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-bas

Quantitative assessment shows loss of antigenic epitopes as a function of pre-analytic variables

Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial.

Proliferation marker Ki-67 in early breast cancer.

P304

1656-1664

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JNCI/DJR393

http://www.w3.org/2001/XMLSchema#string

P407

P433

22

http://www.w3.org/2001/XMLSchema#string

P478

103

http://www.w3.org/2001/XMLSchema#string

P50

Frédérique Penault-Llorca

P577

2011-09-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51682863

http://www.w3.org/2001/XMLSchema#string

P698

21960707

http://www.w3.org/2001/XMLSchema#string

P932

3216967

http://www.w3.org/2001/XMLSchema#string